Basal cell carcinoma is a type of skin cancer. Basal cell carcinoma begins in the basal cells a type of cell within the skin that produces new skin cells as old ones die off. Basal cell carcinoma often appears as a slightly transparent bump on the skin, though it can take other forms. Basal cell carcinoma occurs most often on areas of the skin that are exposed to the sun, such as head and neck. It is more common among fair-skinned people with sun exposure and is very rare among dark-skinned people.
Market Dynamics
Key players operating in the global basal cell carcinoma market are focusing on adoption of growth strategies such as product launch, regulatory approval, and research and development for the treatment of basal cell carcinoma, which is expected to drive the market growth during the forecast period. For instance, in January 2021, Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, announced dose administration for the first patient in a phase 2a clinical study of the company's lead drug candidate, STP705, for the treatment of cutaneous basal cell carcinoma. Moreover, in November 18 2021, Verrica Pharmaceuticals Inc., a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, announced that the U.S. Food and Drug Administration had accepted the company’s investigational new drug application for LTX-315, a potential first-in-class oncolytic peptide, for the treatment of basal cell carcinoma. The company expects to initiate its phase II trial of LTX-315 in basal cell carcinoma in the first quarter of 2022.
Key features of the study:
- This report provides in-depth analysis of the global basal cell carcinoma market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global basal cell carcinoma market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Merck & Co., Inc., Sun Pharmaceutical Industries Ltd., Novartis AG., Bausch & Lomb Incorporated., Allergan, Perrigo Company plc, Taro Pharmaceutical Industries Ltd., Provectus Biopharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, Sanofi, and Mylan N.V.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global basal cell carcinoma market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global basal cell carcinoma market
Detailed Segmentation:
- Global Basal Cell Carcinoma Market, By Treatment Type :
- Surgical
- Surgical Excision
- Electrodessication & Cutterage ED&C
- Moh's Surgery
- Cryosurgery
- Drugs
- Topical Treatment
- Advanced Medication
- Other
- Others
- Radiation Therapy
- Photodynamic Therapy PDT
- Laser Therapy
- Global Basal Cell Carcinoma Market, By End User :
-
- Hospitals
- Specialty Clinics
- Others
- Global Basal Cell Carcinoma Market, By Region:
- North America
- By Treatment Type
- Surgical
- Surgical Excision
- Electrodessication & Cutterage ED&C
- Moh's Surgery
- Cryosurgery
- Drugs
- Topical Treatment
- Advanced Medication
- Other
- Others
- Radiation Therapy
- Photodynamic Therapy PDT
- Laser Therapy
- By End User
- Hospitals
- Specialty Clinics
- Others
- By Country
- Latin America
- By Treatment Type
- Surgical
- Surgical Excision
- Electrodessication & Cutterage ED&C
- Moh's Surgery
- Cryosurgery
- Drugs
- Topical Treatment
- Advanced Medication
- Other
- Others
- Radiation Therapy
- Photodynamic Therapy PDT
- Laser Therapy
- By End User
- Hospitals
- Specialty Clinics
- Others
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Treatment Type
- Surgical
- Surgical Excision
- Electrodessication & Cutterage ED&C
- Moh's Surgery
- Cryosurgery
- Drugs
- Topical Treatment
- Advanced Medication
- Other
- Others
- Radiation Therapy
- Photodynamic Therapy PDT
- Laser Therapy
- By End User
- Hospitals
- Specialty Clinics
- Others
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Treatment Type
- Surgical
- Surgical Excision
- Electrodessication & Cutterage ED&C
- Moh's Surgery
- Cryosurgery
- Drugs
- Topical Treatment
- Advanced Medication
- Other
- Others
- Radiation Therapy
- Photodynamic Therapy PDT
- Laser Therapy
- By End User
- Hospitals
- Specialty Clinics
- Others
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Treatment Type
- Surgical
- Surgical Excision
- Electrodessication & Cutterage ED&C
- Moh's Surgery
- Cryosurgery
- Drugs
- Topical Treatment
- Advanced Medication
- Other
- Others
- Radiation Therapy
- Photodynamic Therapy PDT
- Laser Therapy
- By End User
- Hospitals
- Specialty Clinics
- Others
- By Country
- GCC
- Israel
- Rest of Middle East
- Africa
- By Treatment Type
- Surgical
- Surgical Excision
- Electrodessication & Cutterage ED&C
- Moh's Surgery
- Cryosurgery
- Drugs
- Topical Treatment
- Advanced Medication
- Other
- Others
- Radiation Therapy
- Photodynamic Therapy PDT
- Laser Therapy
- By End User
- Hospitals
- Specialty Clinics
- Others
- By Region/Country
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Merck & Co., Inc.,*
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sun Pharmaceutical Industries Ltd
- Novartis AG
- Bausch & Lomb Incorporated.
- Allergan
- Perrigo Company plc
- Taro Pharmaceutical Industries Ltd
- Provectus Biopharmaceuticals, Inc.
- F. Hoffmann-La Roche Ltd
- Sanofi
- Mylan N.V.
“*” marked represents similar segmentation in other categories in the respective section.
